Skip to main content

Regulatory Framework Overview

DGDA · Ministry of Health & Family Welfare · Drug and Cosmetics Act 2023

The Directorate General of Drug Administration (DGDA)​

The Directorate General of Drug Administration (DGDA) is Bangladesh's primary regulatory authority for pharmaceuticals, medical devices, cosmetics, and related health products. The DGDA operates under the Ministry of Health and Family Welfare and has jurisdiction over:

  • Importation, manufacture, distribution, and sale of drugs and medical devices
  • Licensing of manufacturers and importers
  • Registration of medical device products
  • Pricing oversight — the DGDA has a price-fixing role for drugs and devices
  • Post-market surveillance and enforcement
  • Issuance of export documentation (Free Sale Certificates, GMP Certificates)

DGDA Structure​

The DGDA is headed by the Director General and operates through a network of offices including field offices that monitor the supply chain at district and divisional levels. The central office handles registration applications, licensing, and national-level policy.

Primary Legislation — Drug and Cosmetics Act 2023​

The Drug and Cosmetics Act, 2023 (effective 18 September 2023) is the governing legislation for medical devices. This Act:

  • Replaced the legacy Drugs Act, 1940 — the most significant regulatory reform in Bangladesh in over 80 years
  • Explicitly included software as a medical device (categorised as a "Drug")
  • Formalised a class-based registration framework (Class A, B, C, D)
  • Strengthened enforcement provisions including Drug Court proceedings
  • Clarified local entity requirements — all registrations must be held by a Bangladesh entity

The Drug Rules, 1946 continue to apply to certain aspects of manufacturing and import oversight pending the issuance of new Rules under the 2023 Act.

GHTF Alignment​

Bangladesh's classification and registration framework follows Global Harmonization Task Force (GHTF) guidance — the same framework adopted by many South and Southeast Asian markets. This means:

  • Four-class risk system (A–D) consistent with GHTF/IMDRF principles
  • Essential principles of safety and performance aligned with GHTF documents
  • ISO 13485 and ISO 14971 recognised as the relevant QMS and risk management standards
  • Documentation requirements broadly consistent with GHTF submission dossier guidance

Strategic implication: Manufacturers with existing FDA 510(k)/PMA, CE marking, TGA registration, or Health Canada licence will find that their documentation packages are largely applicable to the Bangladesh DGDA registration dossier with appropriate local adaptations.

Local Entity Requirement​

All DGDA device registrations must be held by a Bangladesh-registered entity. Foreign manufacturers cannot register directly. This local entity — the Authorized Representative (AR) — holds the registration licence and is fully accountable to the DGDA. See Who Needs to Comply? and Import Licensing & Local Rep.

Quarterly Review Cycle — BD-Unique​

A distinctive feature of the DGDA process is that application completeness is reviewed quarterly — not on a rolling basis. Applications received between review cycles queue until the next scheduled review. This means submission timing relative to the quarterly cycle can materially affect your registration timeline. See Registration Timeline for strategic guidance.

Price Controls — BD-Unique​

The DGDA has authority to fix prices for drugs and medical devices in Bangladesh. This price-fixing role means that registered product prices are subject to DGDA oversight and manufacturers/ARs must comply with pricing requirements. Price changes may require DGDA notification or approval.